Yiming Cell is a one-stop gene drug CDMO service platform, dedicated to the development and application of cell and gene therapy technologies, and can provide overall solutions for gene therapy R&D, clinical, and industrialization. Its business covers cell and gene therapy innovative drugs CRO, CDMO service. Recently, Yiming Cell completed a series C financing of hundreds of millions of RMB. This round of financing was led by GoldStone Investment’s National Strategic Transformation and Upgrading Fund, GoldStone Health Fund, and Lyon Capital’s flagship Chinese market dollar fund. Huagai Capital, Fangfu Capital, IDG Capital, etc. continued to increase their weight.
This article is reproduced from: https://www.itjuzi.com/investevent/13569561
This site is for inclusion only, and the copyright belongs to the original author.